GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shenzhen Neptunus Interlong Bio-Technique Co Ltd (HKSE:08329) » Definitions » Debt-to-Asset

Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) Debt-to-Asset : 0.07 (As of Jun. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Shenzhen Neptunus Interlong Bio-Technique Co Debt-to-Asset?

Shenzhen Neptunus Interlong Bio-Technique Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was HK$93 Mil. Shenzhen Neptunus Interlong Bio-Technique Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was HK$9 Mil. Shenzhen Neptunus Interlong Bio-Technique Co's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was HK$1,534 Mil. Shenzhen Neptunus Interlong Bio-Technique Co's debt to asset for the quarter that ended in Jun. 2024 was 0.07.


Shenzhen Neptunus Interlong Bio-Technique Co Debt-to-Asset Historical Data

The historical data trend for Shenzhen Neptunus Interlong Bio-Technique Co's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhen Neptunus Interlong Bio-Technique Co Debt-to-Asset Chart

Shenzhen Neptunus Interlong Bio-Technique Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 0.01 0.08 0.06 0.06

Shenzhen Neptunus Interlong Bio-Technique Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.06 - 0.06 0.07

Competitive Comparison of Shenzhen Neptunus Interlong Bio-Technique Co's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Shenzhen Neptunus Interlong Bio-Technique Co's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shenzhen Neptunus Interlong Bio-Technique Co's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shenzhen Neptunus Interlong Bio-Technique Co's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Shenzhen Neptunus Interlong Bio-Technique Co's Debt-to-Asset falls into.



Shenzhen Neptunus Interlong Bio-Technique Co Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Shenzhen Neptunus Interlong Bio-Technique Co's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(93.973 + 4.124) / 1548.404
=0.06

Shenzhen Neptunus Interlong Bio-Technique Co's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(92.877 + 8.859) / 1534.079
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shenzhen Neptunus Interlong Bio-Technique Co  (HKSE:08329) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Shenzhen Neptunus Interlong Bio-Technique Co Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Shenzhen Neptunus Interlong Bio-Technique Co's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Shenzhen Neptunus Interlong Bio-Technique Co Business Description

Traded in Other Exchanges
N/A
Address
95 Queensway, 18th Floor, United Centre, Admiralty, Hong Kong, HKG
Shenzhen Neptunus Interlong Bio-Technique Co Ltd is engaged in the research and development, manufacturing, and selling of medicines and medical devices. It is also involved in the purchase and sales of medicines and healthcare food products. The group's revenue and results from operations are mainly derived from activities in the PRC. The operating segments of the company are the Manufacturing and selling of medicines; and the Sales and distribution of medicines and healthcare products. The majority of revenue is generated from the Manufacturing and selling of medicines.

Shenzhen Neptunus Interlong Bio-Technique Co Headlines

No Headlines